Shares of Cara Therapeutics Inc. (NASDAQ:CARA) rocketed 42.8 percent Wednesday on word of the Stamford, Conn.-based company's global licensing deal with Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), a chronic kidney disease (CKD)-focused joint venture (JV) formed by Vifor Pharma Group and Fresenius Medical Care. The arrangement covers the injectable formulation of difelikefalin (CR-845), conditionally branded Korsuva, to treat CKD-associated pruritus (CKD-aP), which has advanced into a pivotal phase III program.